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Low birthweight due to intrauterine growth restriction is associated with metabolic
disorders after birth. Our 1st study assessed deficits in skeletal muscle glucose metabolism and
pancreatic β cell function in IUGR fetal sheep. We aimed to evaluate the effectiveness of daily
intravenous infusions of the anti-inflammatory ω-3 polyunsaturated fatty acid (PUFA),
eicosapentaenoic acid (EPA), as a means of improving deficits previously observed in the IUGR
fetus by targeting fetal systemic inflammation. The presence of systemic inflammation in IUGR
fetuses was evident by increased total circulating populations of total leukocytes, lymphocytes,
and monocytes. However, these were decreased by 5-day ω-3 PUFA infusions. Additional blood
parameters including lactate and CO2 were increased in IUGR fetuses, regardless of infusion of
EPA. Poor β cell function in IUGR fetuses was improved by EPA infusion, as evident by
improved circulating plasma insulin, O2, CO2, HCO3, Na+, K+, and Cl- during a hyperglycemic
clamp. Hindlimb glucose uptake and oxidation rates, which were impaired by IUGR were
improved by EPA infusion as well. These findings indicate that targeting systemic fetal
inflammation by infusion of the anti-inflammatory ω-3 PUFA, EPA, many IUGR-associated
deficits in glucose metabolism and β cell function in the IUGR fetal sheep were resolved.

Our 2nd study sought to determine the effectiveness of daily EPA infusions on fetal
growth biometrics and skeletal muscle-specific deficits associated with IUGR. In IUGR fetuses,
decrease in mass were observed for whole fetus, hindlimb, semitendinosus, soleus, longissimus
dorsi, lungs, and kidneys, but 5-day EPA infusion improved most of these deficits. The fiber
type ratios of skeletal muscle estimated by myosin heavy chain proportions were also altered by
IUGR but were recovered by EPA infusion as well. Ex vivo glucose uptake and oxidation
capacities were impaired in IUGR muscle but were improved after daily EPA infusions. Results
from this study indicate that daily fetal ω-3 PUFA infusions of EPA were effective in improving
fetal growth biometrics, body composition, and muscle-specific glucose metabolism.
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Chapter 1
Literature Review

Introduction
The physiological response to any external stimulus defines the result to that event. Whether to
everyday life events or catastrophic insults, bodily responses to events define how life will move
forward. Everitt (1968) discussed the extent to which future responses are altered by events that
occur during fetal development. Subsequent epidemiological studies have defined the concept of
fetal programming and the thrifty metabolic phenotype hypothesis was established in the early
1990’s (Hales and Barker, 1992; Godfrey and Barker, 2000). The building literature in this field
show that detrimental effects of maternal stress during critical windows of fetal development
cannot be overstated. Intrauterine growth restriction (IUGR) is the phenotypic result of poor
intrauterine conditions causing nutrient-sparing metabolic and growth deficits that predispose
individuals to a multitude of metabolic disorders (Thorne et al., 2014; Brown et al., 2015). Fetal
adaptations occur to aid fetal survival but the repartitioning of fetal nutrients toward vital organs
and tissues occurs at the expense of fetal growth and glucose homeostasis (Yates et al., 2014;
Yates et al., 2018). Using the well-characterized heat stress model for placental insufficiency
induced IUGR (PI-IUGR) in the ovine, we have previously reported links between adrenergic
and inflammatory signaling pathways, reduced fetal growth, and metabolic inefficacy (Cadaret et
al., 2019a; Posont and Yates, 2019). We also found that post-natal supplementation yielded
increased body performance in IUGR-born offspring. Although this provides a basis for
treatment of pathologies once established, there is a gap in literature regarding interventions for
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these mechanisms before they become pathogenic. Thus, the basis for prenatal treatment
targeting fetal systemic inflammation has yet to be determined.

Intrauterine Growth Restriction
Prenatal Stress & Developmental Programming Mechanisms.
Fetal growth is contingent upon many factors, including environmental and maternal influences.
However, alterations to these influences result in changes to the intrauterine environment,
producing IUGR (Murphy et al., 2006; Scifres and Nelson, 2009). Poor intrauterine conditions in
late gestation induce fetal survival mechanisms and adaptations that result in IUGR (Murphy et
al., 2006). Individuals born IUGR are at an increased risk for perinatal morbidity and mortality.
The largely muscle-centric adaptations that induce metabolic dysfunction result from chronic
maternal stress that is almost always associated with placental insufficiency (PI-IUGR)
(Limesand et al., 2007). IUGR-born individuals are predisposed to an increased risk of poor
thermoregulation, hypoglycemia, cardiac dysfunction, and infection (Limesand et al., 2007;
Gaccioli and Lager, 2016). However, consequences are not limited to the fetal stage as fetal
programming mechanisms yield lifelong greater risk of metabolic and cardiovascular disorders
and growth deficits (Barker et al., 2006).
Maternal Causes of IUGR. Although etiologies of placental insufficiency in human and livestock
pregnancies are still being studied, previous literature indicates the impact of known risk factors
such as pre-eclampsia, hypertensive disorders, maternal drug use, decreased interpregnancy
intervals nutritional intake, and environmental stressors (Hendrix and Berghella, 2008; Limesand
et al., 2018; Yates et al., 2018; Wardinger and Ambati, 2021). The result of these maternal
stressors is compromised placental development that is characterized by decreased placental
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vascularity, oxygen permeability, and transporters required for fatty acid and glucose transport to
the fetus (Thorn et al., 2011; Limesand et al., 2018). Reduced maternal blood flow to the fetus
and umbilical-placental vascular resistance further compound the functional deficits of the
placenta and worsen hypoperfusion of glucose and fatty acid in particular (Wardinger and
Ambati, 2021). A summary of the hallmark fetal pathologies created in late gestation by
placental insufficiency is presented in Table 1-1.
Placental Insufficiency Induces IUGR. As the facilitator of nutrient and waste exchange between
the dam and the fetus, the placenta is a crucial regulator of fetal growth and, specifically, the
ability for the fetus to meet its growth potential (Murphy et al., 2006). The placenta is a
metabolically-active tissue that utilizes nutrients and oxygen for its own independent growth as
well as providing these substrates to the fetus by simple diffusion and transporter-mediated
transfer (Barry et al., 2008). However, when these processes are impeded by placental stunting
due to maternal stress, both placental growth and the maternofetal interface are compromised. In
animal models, placental insufficiency is characterized by as much as 50% decreased total
placental mass (Brown et al., 2015), as well as reductions in placental villous number, diameter,
surface area, and degree of branching (Barry et al., 2008). In addition, impaired synthesis of
Nitric Oxide and polyamines is observed in the stunted placenta (Wu et al., 2006). In a study by
Limesand et al. (2007), IUGR placentas collected near term in sheep weighed 61% less than
control placentas (P < 0.01). During peak fetal growth in late gestation, delivery of
carbohydrates, amino acids, and oxygen by the placenta must meet metabolic demand for rapid
fetal growth. However, when placental stunting occurs, the stunted placenta cannot deliver
sufficient oxygen and nutrients to the developing fetus. Thus, the fetus is compromised by a
limited supply of nutrients, particularly, amino acids, glucose, and oxygen (Limesand et al.,
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2007; Brown et al., 2015; Pendleton et al., 2021). The deprivation of these nutrients due to
placental insufficiency ultimately lead the fetus to respond with nutrient-sparing programming
that includes insulin resistance, impaired growth, and altered metabolic processes (Dunlop et al.,
2015).
Physiological Responses of the Fetus to Placental Insufficiency. The fetal response to
intrauterine stress is necessary for prenatal survival but also ultimately creates postnatal
consequences for these individuals. The fetal stress response is characterized by increased
secretion of catecholamines, pro-inflammatory cytokines, hypoxia, hypoglycemia, and
hyperlactatemia (Yates et al., 2014; Cadaret et al., 2019c). As an innate survival mechanism,
nutrient-sparing mechanisms are enacted to provide the essential organs with necessary
substrates (Limesand et al., 2007). However, these developmental mechanisms reduce growth
potential as the fetus adapts to being deprived of nutrients for less essential mechanisms such as
myogenesis (Yates et al., 2018). Because skeletal muscle is a crucial regulator of glucose
homeostasis, impaired development impacts metabolic health. More direct adaptive
programming mechanisms in muscle include changes in metabolic processes that limit capacity
for oxidative metabolism and increased lactate production (Brown et al., 2015; Cadaret et al.,
2019c).
Nutrient Repartitioning at the Expense of Skeletal Muscle. A key fetal adaptation is redistribution
of cardiac output towards the body’s most vital organs such as the brain and adrenal glands
(Dunlop et al., 2015). This acute survival mechanism allows these organs to maintain adequate
growth and development but at the expense of other tissues and organs such as the heart,
kidneys, and skeletal muscle. Near term and after birth, the consequences are made apparent by
asymmetric body composition (Hales and Barker, 1992). Although it only composes
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approximately 40% of the fetal body mass, skeletal muscle is responsible for 85% of fetal
insulin-stimulated glucose metabolism (Brown, 2014; Hicks and Yates, 2021). Thus,
compromised skeletal muscle growth and metabolism is the primary cause for glucose metabolic
deficits in the IUGR fetus. The metabolic shift that inherently yields such biometric deficits are
characterized by decreased mitochondrial metabolic capacity which couples oxygen
consumption with substrate utilization (Pendleton et al., 2021). Although this mechanism is a
barrier for muscle growth and development, it increases lactate production as a mechanism for
providing carbon substrates for hepatic glucose production, which helps maintain glucose for
brain development (Brown et al., 2015).
Because these adaptations are programmed, metabolic impairment and growth deficits persist
after parturition even though oxygen and nutrient supply is no longer limited. Individuals
maintain this thrifty phenotype, and increased fat deposition ultimately results. This further
compromises intracellular regulation of insulin secretion and responsiveness, resulting in
dysregulation of blood glucose concentrations and insulin resistance in muscle and adipose tissue
(Limesand et al., 2007; Gibbs et al., 2020).
Fetal Programming Mechanisms. Metabolic adaptations that limit the oxidative capacity of
skeletal muscle occur at the molecular level (Pendleton et al., 2021). These changes can include
increased PDK1. This in turn inhibits PDH activity and its conversion of pyruvate to acetyl coA,
which is the entry point for glucose into the TCA cycle that feeds into the electron transport
chain. This helps explain the suppression of glucose oxidation even when glucose uptake is not
impaired (Brown et al., 2015). Furthermore, a 4-fold increase in PDK4 expression in IUGR fetal
skeletal muscle observed by Brown et al. (Brown et al., 2015) was likewise associated with a 1015% reduction in IUGR fetal glucose oxidation, suggesting dynamic molecular changes
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underlying limited capacity for glucose oxidation. The combination of normal glucose uptake by
reduced entry into the TCA cycle means that skeletal muscle lactate production is increased, as
illustrated by Figure 1-1. Despite concurrent insulin insensitivity, this typically equates to a
lesser fraction of glucose being oxidized under both basal and insulin-stimulated conditions
(Limesand et al., 2007; Brown et al., 2015). Work by our lab demonstrates the persistence of
impaired muscle glucose oxidation at the neonatal and juvenile stages, despite the stress being
alleviated by birth (Limesand et al., 2007; Gibbs et al., 2020).
The Health Impact of IUGR Pathologies.
The maternal etiology of IUGR can be variable, with many different environmental, nutritional,
or lifestyle conditions leading to the multifaceted reduced functional capacity of the placenta.
The fetal and postnatal outcomes that result, however, are more consistent and hallmarks of
impaired metabolic function in IUGR offspring include hypertension, obesity, diabetes, and
increased risk of cardiovascular diseases (Dunlop et al., 2015). The same molecular pathologies
occur when pregnant livestock face chronic stress, and thus IUGR-born animals also exhibit poor
growth and metabolic inefficiency. Therefore, IUGR is a relevant issue that must be addressed in
both humans and livestock.
Relevance of IUGR in Humans. Although several common causes of maternal stressors have
been linked to IUGR in human pregnancies, nearly 50% of IUGR cases occur as the result of an
unidentified cause (Al-Azemi et al., 2017). IUGR adaptations can effect metabolic function even
when growth restriction is mild and does not qualify clinically as small for gestational age (SGA)
birthweight, which means that it and can be misdiagnosed when only bodyweight is measured
(Cyrkowicz and Czekański, 1998). In fact, SGA individuals are classified by healthy, well-
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nourished infants with a smaller and shorter frame in the 10th percentile whereas IUGR is
associated with asymmetric body metrics and ultrasound-diagnosed uteroplacental deficiencies
(Cyrkowicz and Czekański, 1998; Boehmer et al., 2017). In other words, SGA can occur
independent of IUGR and conversely, IUGR does not always fit the clinical parameters for SGA.
Nevertheless, IUGR is reported to afflict up to 53 million infants globally each year (Sedgh et
al., 2014). Because of challenges associated with global healthcare, only 4-8% of cases are
diagnostically linked to placental insufficiency (Boehmer et al., 2017). Fleiss et al. (2019)
estimated that the rate of IUGR in human populations without confounding conditions to be up
to 9%. However, the rate is exacerbated in lower-resource populations to as high as 30% (Fleiss
et al., 2019). In addition to greater perinatal morbidity and mortality, these individuals are at 18fold greater risk for metabolic disorders that reduce the length and quality of life, including Type
2 diabetes, obesity, hypertension, and hyperlipidemia (Gatford et al., 2010; Yates et al., 2018;
Hicks and Yates, 2021).
Relevance of IUGR in Livestock. IUGR is also a relevant issue in livestock production where low
birthweight due to IUGR occurs in approximately 10% of all livestock but can effect entire herds
during harsh environmental or nutritional conditions (Wu et al., 2006). This contributes to an
estimated annual loss of $12.1 billion in revenue (USDA, 2017) for producers due to a
combination of poor growth performance, carcass merit discounts, and death loss (Smith et al.,
1995; Boleman et al., 1998; Posont and Yates, 2019). Although most low-birthweight offspring
survive the perinatal stage, decreased vigor and health further reduce the economic feasibility of
having these individuals in the herd. As the animal ages, decreased muscle growth coupled with
increased visceral fat compromise carcass value at the slaughterhouse due to less yield and
smaller high-value cuts (Greenwood et al., 2000). Although studies are beginning to identify
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underlying mechanisms and the issue has long been recognized by the industry, IUGR continues
to cost the livestock producers 8% of their annual product, which is equal to the loss of 3 million
beef calves, 930,000 dairy calves, and 530,000 lambs each year (Wu et al., 2006; Yates et al.,
2018).
Sheep as a Model for IUGR. With the need to understand and treat IUGR in both humans and
animals, ovine models have become popular tools to study fetal and placental growth restriction.
Using the pregnant sheep as a physiological model is ideal for a multitude of reasons, including
similar developmental milestones as humans and cattle, tolerance for surgical and experimental
manipulation during gestation, and the translation of IUGR outcomes that are highly comparable
to humans and cattle (Regnault, 2003; Beede et al., 2019). The induction of IUGR in the sheep
model can be accomplished using several methods, including chronic maternal hyperthermia,
overnutrition of the dam at a young age, chronic maternofetal inflammation, nutrient restriction,
and surgical placental reduction (Beede et al., 2019). The frequent use of these models in current
studies show that sheep are an effective model for biomedical and agricultural research aimed at
assessing fetal programming mechanisms.

Inflammatory Pathologies in IUGR
As a part of the stress response to placental insufficiency, IUGR fetuses present physiological
indicators of systemic inflammation, including changes in white blood cell (WBC) populations
and increased inflammatory cytokines which play a vital role in metabolic programming. These
indicators are summarized in Table 1-2. Tumor necrosis factor α (TNFα) and Interleukin-6 (IL6) are major inflammatory cytokines that are secreted from leukocytes during nutritional or
metabolic stress, typically in response to increased reactive oxygen species (ROS) or other stress
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signals (Renshaw et al., 2010). In a study by Al-Azemi et al. (2012), the increased relevance of
inflammation in the PI-IUGR fetus in comparison to IUGR fetuses produced from other methods
was abundant as increased IL-2 and IL-12 suggested a propensity towards Th1 expression and
subsequent TNFα secretion in the PI-IUGR fetus. Moreover, decreased IL-4 and increased IL-10
concentrations in non-PI IUGR fetuses further supported the correlation between inflammation
and placental insufficiency (Al-Azemi et al., 2017).
Stress-induced cytokine Production. Although most commonly associated with immune
responses, cytokines and other inflammatory factors are parts of the general stress response and
metabolic regulation. Cytokines are produced in large quantities by macrophages located in
circulation and peripheral tissues. These proteins can be secreted locally or systemically and are
elevated in the IUGR fetus (Irani et al., 2009; Cadaret et al., 2019c). The secretion of T helper 1
(Th1) and T helper 2 (Th2) cells regulate these mechanisms by their individual roles in the
immune response (Al-Azemi et al., 2017). Th1 cells are responsible for the secretion of
inflammatory cytokines such as TNFα and IL-2, which activate macrophages in cell-mediated
immunologic responses, whereas Th2 cells secrete anti-inflammatory cytokines such as IL-4, IL5, and IL-10 (Al-Azemi et al., 2017).
In adult animals, presence of oxidative stress is indicated by alterations in WBC profiles in
circulation, including increases in leukocytes, granulocytes, lymphocytes, and monocytes as well
as of inflammatory cytokines (Barnes et al., 2019; Swanson et al., 2020). Romero et al. (1998)
cited the strong correlation of elevated cytokine concentrations in fetal blood and amniotic fluid
and acknowledged that both of these were indicators of pre-term labor. However, maternal IL-6
was not correlated with fetal concentrations in that study. Therefore, increased cytokines in the
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fetus imposed stress induced adaptations, and these conditions were not correlated with pre-term
labor.
Impaired Skeletal Muscle Growth. Fetal hyperplasia determines postnatal muscle fiber number
and thus is crucial in establishing muscle growth potential. In livestock, this can have a major
impact on meat yield and quality (Hegarty and Allen, 1978; Greenwood et al., 2000). Adaptive
changes in IUGR muscle impair myogenesis by disrupting cellular signaling for proliferation and
differentiation of muscle stem cells called myoblasts (Yates et al., 2014; Posont and Yates,
2019). These cause long term impacts for total muscle mass and growth potential as the animal
ages (Bell, 2006). Although acute stimulation by cytokines promotes growth and development of
skeletal muscle, prolonged exposure is one mechanism whereby proliferation and differentiation
of myoblasts are restricted in the IUGR fetus (Posont and Yates, 2019). Because myoblast
function is a rate-limiting process for muscle growth, the functional impairment by persistent
exposure to cytokines in utero can be considered a key mechanism for decreased hypertrophic
growth capacity (Cadaret et al., 2019b).
Inflammatory Effects on Glucose Metabolism & Insulin Secretion. Activation of the Nuclear
Factor κ-B (NFκB) pathway by TNFα and other cytokines contributes to the shift toward
muscle-centric glucose metabolism by inhibiting insulin-stimulated Akt phosphorylation and
subsequent decreased translocation of GLUT-4 transporters for glucose uptake (Lorenzo et al.,
2008; Cadaret et al., 2017). This directly and indirectly helps explain deficient glucose oxidation
capacity in IUGR skeletal muscle (Cadaret et al., 2019a; Posont et al., 2021b).
Pancreatic islet cells are also affected by inflammation as proper IL-6 exposure promotes
microvasculature development of the islets (Limesand et al., 2007). However, chronic exposure
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to systemic inflammation is detrimental to islet size, density, and pancreatic mass (Boehmer et
al., 2017). These anatomical deficits in islets lead to alterations in function, as IUGR fetuses
exhibit altered gene expression for PDX1 and other regulatory factors, thus contributing to
defects in β-cell replication and decreased insulin content (Limesand et al., 2007; Green et al.,
2010; Boehmer et al., 2017).

ω-3 Polyunsaturated Fatty Acids as Anti-Inflammitants
In pregnant women, common additives to prenatal vitamins include eicosapentaenoic acid (EPA)
and docasohexanoic acid (DHA), as studies support the benefits of the ω-3 polyunsaturated fatty
acids (ω-3 PUFAs) in fetal neurodevelopment, immune system development, and central
nervous system health (Greenberg et al., 2008; Best et al., 2016). Although these ω-3 PUFAs can
be synthesized from ⍺-linoleic acid (ALA) in the adult, the developing fetus does not have this
ability and thus the only derivatives come from placental transfer as excess after satisfying the
metabolic needs of the mother (Larque et al., 2012). Studies have established the capacity for ω3 PUFAs to mitigate inflammatory pathways and also promote the production and secretion of
anti-inflammatory cytokines (Chen et al., 2017; Inoue et al., 2017; Gonzalez-Soto and Mutch,
2021). Epidemiological studies in the past have associated the consumption of long-chain ω-3
PUFAs with decreased risk of inflammatory syndromes such as arthritis and pulmonary vascular
resistance (Sharma et al., 2017). The designation between ω-3 PUFAs, which are antiinflammatory, and ω-6 PUFAs, which can increase inflammatory tone, is determined by whether
a double bond is located at the 3rd or 6th carbon from the terminal methyl group, respectively
(Kim et al., 2019). As illustrated in Figure 1-2, EPA is a carboxylic acid chain that is 20 carbons
in length and contains five double bonds, the 1st of which is located at the 3rd carbon (designating
it as an ω-3). DHA is a carboxylic acid that is 22 carbons in length with six cis double bonds, the
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1st of which is located at the 6th carbon from the terminal methyl. Both EPA and DHA are
synthesized from the essential fatty acid, ALA, although the process is energetically costly
(Burdge and Calder, 2005). This stepwise process has several intermediate steps but begins with
the desaturation of ALA to stearidonic acid by delta-6-desaturase. It is this 1st step that is rate
limiting, however. Next, elongase converts stearidonic acid into eicosatetraenoic acid and finally
to EPA by delta-5-de-saturase (Lenihan-Geels and Bishop, 2016). ALA is highly abundant in
common foods such as flaxseed, soybean, and canola whereas EPA and DHA can be obtained
directly from fish, seaweed, and algae without having to be synthesized by the body. In order to
be metabolized for energy, these PUFAs enter the cellular matrix as an acyl-carnitine by way of
a carnitine transporter before phosphorylation back to a fatty acid, which can then undergo βoxidation (Burdge and Calder, 2005). As a nutraceutical, EPA induced a 25% decrease in
pulmonary vascular resistance in fetal lambs, whereas DHA had no effect (Sharma et al., 2017).
Literature provides comprehensive evidence that ω-3 PUFA inhibit many aspects of
inflammation including decreased cytokine and eicosanoid production (Caughey et al., 1996;
Velten et al., 2014; Allam-Ndoul et al., 2016). Moreover, the expression of transcription factors
inhibits the activity of the NFκB pathway (Allam-Ndoul et al., 2016). Therefore, the capacity for
ω-3 PUFA to mitigate inflammatory pathologies is established.
During late gestation, fatty acids are required for brain and adipose tissue development but may
only be acquired from the maternal diet via placental transfer (Murphy et al., 2006). This
transport can occur in several ways, including the use of fatty acid transport proteins (FATP)-1,
2, 3, 4, 5, 6 and fatty acid binding protein (FABP) -1, 3, 4, 5, 7 (Devarshi et al., 2019). As
circulating maternal concentrations of EPA and DHA increase, placental mRNA expression of
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these FATP is also upregulated, and subsequent increase of these PUFA in cord blood are
observed, along with the FABP required for their placental transfer (Greenberg et al., 2008).
The cumulative alterations in white blood cells and cytokine profiles are hallmarks of systemic
inflammation and likewise, hallmarks of IUGR. Thus, ω-3 PUFA provide promise to mitigate
inflammatory signaling its programmed deficits in the IUGR fetus. As transporter mechanisms
are upregulated during gestation, we know that these nutraceuticals have the ability to be
transported across the placenta and therefore provide promise in future treatment through
maternal ingestion (Connor et al., 1996; Greenberg et al., 2008).

Conclusion
Work by our lab and others continue to characterize the mechanistic deficits of underlying IUGR
that contribute to lifelong metabolic and biometric deficits in humans and livestock. Although
these mechanisms are beginning to be identified, little is known regarding how they may be
mediated in utero. The objectives of the following studies were aimed at establishing a basis for
how fetal systemic inflammation may be alleviated by nutraceutical intervention during late
gestation. Specifically, the effectiveness of direct fetal infusion of ω-3 PUFA on IUGR fetal
growth and metabolic outcomes was evaluated by measuring fetal biometrics, β-cell function,
skeletal muscle glucose uptake, and skeletal muscle oxidative metabolism in a well-characterized
sheep model for placental insufficiency and IUGR.
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Figure 1-1. Simple Diagram of the part of glucose metabolism pathway which is being altered by IUGR
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Figure 1-2. Biochemical Structures of ⍺-linoleic acid (ALA), eicosapentaenoic acid (EPA), and
docosahexaenoic acid (DHA).
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Table 1-1. Summary of the physiological parameters which are altered in the IUGR fetus.

Physiological Parameter

Conditions in the IUGR Fetus

O2

~60% ↓ arterial blood oxygen (Brown et al., 2015); ~50% ↓
fetal oxygen (Macko et al., 2016)

Lactate

4-fold ↑ lactate concentrations (Brown et al., 2015);

Insulin

~55% ↓ insulin concentrations (Brown et al., 2015);
~69% ↓ insulin concentrations (Limesand et al., 2007);
~56% ↓ β-cell mass (Leos et al., 2010)

Glucose

~50% ↓ glucose concentrations (Limesand et al., 2007);
~ 30% ↓ glucose concentrations (Brown et al., 2015);
~50% ↓ glucose oxidation rate (Limesand et al., 2007);

Catecholamines

7-fold ↑ Norepinephrine (Yates et al., 2016); 5-fold ↑
Epinephrine (Limesand et al., 2007)

IGF-1

~ 80% ↓ circulating fetal IGF-1 (Thorne et al., 2009); ~ 33%
↓ fetal arterial IGF-1 (Macko et al., 2016);

PDK4-1

4-fold ↑ PDK4 expression (Brown et al., 2015)

Myoblast Function

~13% ↓ proliferated and
~46% ↓ differentiated myoblasts (Yates et al., 2014); ~12% ↓
myoblast proliferation (Riley et al., 2016); ~50% ↓ crosssectional hindlimb muscle fiber area(Posont et al., 2018)
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Table 1-2. Summary of the indicators of inflammatory signaling in the IUGR fetus.
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Chapter 2
Decreased skeletal muscle glucose metabolism and impaired β cell function in IUGR fetal
sheep were improved by daily ω-3 PUFA infusions.

The findings presented in this chapter were published in the 2021 proceedings of the American
Society of Animal Science, Western Section, which is peer-reviewed.

Lacey, T. A., R. L. Gibbs, M. S. Most, H. N. Beer, Z. M. Hicks, P. C. Grijalva, J. L. Petersen,
and D. T. Yates. 2021. Decreased fetal biometrics and impaired β cell function in IUGR fetal
sheep are improved by daily ω-3 PUFA infusion. Transl. Anim. Sci. 5(Suppl 1) doi:
10.1093/tas/txab168

ABSTRACT
Poor intrauterine conditions created by placental insufficiency result in intrauterine
growth restriction (IUGR) of the fetus. Decreased fetal nutrients and O2 coincide with fetal
inflammation, which appears to have a role in thrifty programming mechanisms, including
reduced skeletal muscle glucose oxidative metabolism. Thus, our objective was to target
inflammation in IUGR fetal sheep by infusing an anti-inflammatory ω-3 polyunsaturated fatty
acid (PUFA), eicosapentaenoic acid (EPA), to improve homeostatic blood parameters and
metabolic outcomes. In this study, IUGR fetuses were produced by maternal hyperthermiainduced placental insufficiency. Surgical placement of indwelling fetal femoral catheters allowed
arterial blood collection and daily intravenous infusion of IUGR fetuses with saline (i.e., IUGR;
n=5) or eicosapentaenoic acid (i.e., IUGR+EPA; n=6) for 5 ± 1 days beginning at 119 ± 1 days
of gestational age (dGA). Controls (n=12) were saline-infused fetuses from thermoneutral ewes.
Daily arterial blood samples were collected to assess complete blood cell count (CBC). Daily
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blood parameters were assessed by arterial blood collection for CBC, blood gases, and
metabolites. Glucose-stimulated insulin secretion was assessed at 122 ± 1 dGA and hindlimbspecific glucose metabolism was determined at 123 ± 1 dGA. Daily circulating white blood cells
(WBC) were elevated (P < 0.05) in IUGR compared to control and IUGR+EPA fetuses. In
addition, platelets were elevated (P < 0.05) in IUGR and IUGR+EPA fetuses compared to
controls. Blood lactate and pCO2 were increased (P < 0.05) in IUGR fetuses compared to
controls however did not differ from IUGR+EPA fetuses. Basal plasma insulin was less (P <
0.05) for IUGR but not for IUGR+EPA fetuses compared to controls. Glucose-stimulated insulin
secretion was less (P < 0.05) for IUGR and IUGR+EPA fetuses compared to controls but was
greater (P < 0.05) for IUGR+EPA than for IUGR fetuses. Blood pO2, pCO2, HCO3, Na+, K+, and
Cl- were less (P < 0.05) for IUGR fetuses than controls but were greater (P < 0.05) for
IUGR+EPA than for IUGR fetuses. BUN and NEFA concentrations were increased (P < 0.05)
for IUGR but not IUGR+EPA fetuses compared to controls. HDLC did not differ between
controls and IUGR fetuses but was increased (P < 0.05) in IUGR+EPA fetuses. Hindlimb
glucose uptake rates were decreased (P < 0.05) for IUGR and IUGR+EPA fetuses and hindlimb
insulin-stimulated glucose oxidation was decreased (P < 0.05) for IUGR and IUGR+EPA
fetuses, compared to controls. These findings demonstrate that infusion of the anti-inflammatory
ω-3 PUFA, EPA, improved some aspects of metabolic dysfunction in the IUGR fetus.
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INTRODUCTION
Placental insufficiency-induced intrauterine growth restriction (IUGR) results in musclecentric fetal programming that impairs glucose metabolism (Yates et al., 2019) and yields
asymmetric growth that favors fat deposition (Gibbs et al., 2020). Decreased nutrients and O2
impose fetal stress, initiating fetal adaptations for survival that also increase the risk for
hypertension, obesity, and Type 2 diabetes after birth (Yates et al., 2011). Chronic exposure of
skeletal muscle and pancreatic islets to inflammatory cytokines appears to be a key culprit for the
programming mechanisms that yield IUGR and in turn life-long metabolic dysfunction (Yates et
al., 2018; Posont et al., 2021b). Thus, the objective of this study was to evaluate the effects of
manipulating stress-induced inflammatory activity in the IUGR fetus. Previous studies have
reported that ω-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory actions and also
stimulate glucose metabolism (Kim et al., 2019). If administration of ω-3 PUFA can effectively
improve glucose metabolism and insulin sensitivity, then glucose homeostasis, metabolic
efficiency, and growth in the IUGR fetus may be recovered. We hypothesized that manipulation
of inflammatory pathways in the skeletal muscle of IUGR fetuses via daily infusion with
eicosapentaenoic acid (EPA) in late gestation would improve fetal blood indicators of metabolic
health, glucose homeostasis, biometric growth, and body composition.

MATERIALS & METHODS
Animals and Experimental Design
All studies were approved by the Institutional Animal Care and Use Committee at the
University of Nebraska-Lincoln, which is AAALAC International-accredited. Time-mated
Polypay ewes were used to produce control and placental insufficiency-induced IUGR fetuses as
previously described (Yates et al., 2016). Briefly, ewes were exposed to ambient conditions of
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40°C and 35% relative humidity from the 40th to the 95th day of gestational age (dGA) before
returning to thermoneutral conditions (25°C) for the duration of the study. Ewes carrying control
fetuses were pair-fed to the average daily intake of the ewes carrying IUGR fetuses. At 118 dGA,
partial cesarean surgeries were performed to place indwelling catheters in the femoral vein and
artery of the fetus and an arterial blood flow probe as previously described (Cadaret et al.,
2019c). On dGA 119 ± 1, IUGR fetuses were randomly assigned to receive daily 1-hour i.v.
infusions of 0.25 mg/d EPA (i.e., IUGR+EPA; n=6) or ethanol-spiked (EtOH) saline placebo
(ie. IUGR; n=5) for 5 ± 1 d. EPA concentrate was suspended in EtOH (Sigma-Aldrich). Control
fetuses (n=12) also received daily EtOH-spiked saline infusions.
Fetal arterial blood samples were collected daily from 120 to 125 dGA. Complete blood
cell counts (CBC) were determined using a HemaTrue Veterinary Chemistry Analyzer (Heska,
Loveland, CO). An ABL90 FLEX blood gas analyzer (Radiometer America, Bera, CA) was used
to measure blood gases and metabolites.
In Vivo Fetal Metabolism
Glucose-Stimulated Insulin Secretion. Pancreatic β cell function was assessed using a
square-wave hyperglycemic clamp at 122 ± 1 dGA as previously described (Cadaret et al.,
2019c). Three arterial samples were taken in 5-minute intervals at baseline (i.e., resting) levels
then a 3 mL bolus of 33% dextrose solution was administered intravenously (i.v.) followed by a
continuous variable-rate infusion in order to achieve steady-state hyperglycemia (i.e., 2.5X
baseline). After steady-state was achieved and at least twenty minutes after the bolus, three
additional arterial samples were taken at 5-minute intervals at hyperglycemia. Blood samples
collected in heparinized syringes were analyzed to measure blood gases and metabolites via
ABL90. Samples collected into EDTA syringes were centrifuged (14,000 x g, 2 minutes, 4°C)
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and plasma was collected and stored at -80°C. Plasma insulin concentrations were then
determined in duplicate using the Bovine Insulin ELISA (Alpco, Salem, NH), which has been
validated for sheep. Plasma NEFA concentrations were calculated via commercial NEFA
colorimetric assay (Sigma-Aldrich). Plasma BUN, and HDLc concentrations were measured by
Vitros 250 Chemistry Analyzer (Biomedical and Obesity Research Core, Lincoln, NE). Interand intra- assay coefficients of variance were below 10%.
In Vivo Hindlimb Glucose Metabolism. Hindlimb-specific glucose metabolism was
estimated by a hyperinsulinemic-euglycemic clamp (HEC) at 123 ± 1 dGA as previously
described (Yates et al., 2019). For this study, fetuses were administered a radiolabeled glucose
tracer (18.75μCi/ml, U-[14C]-glucose; Perkin-Elmer, Waltham, MA) infused at a constant rate of
1 mL/hour following a 1 mL i.v. bolus. Four pairs of simultaneous femoral arterial and venous
samples were then collected at 5-minute intervals to establish a baseline before bolusing 1 mL of
33% dextrose (150 mg/kg, i.v.) and 2mL of insulin (250 mU/kg; Humulin-R, Eli Lilly,
Indianapolis, IN). A variable-rate infusion of 33% dextrose was used to maintain euglycemia.
Insulin was infused at a constant rate of 0.5 ml/kg/hour until steady state HEC was achieved
(±10% baseline glucose). Four more pairs of simultaneous arterial and venous samples were then
taken at 5-minute intervals. Samples were analyzed for blood gases and metabolites via ABL90
and plasma was isolated and collected to be stored at -80°C until insulin concentrations were
determined via Bovine Insulin ELISA.
Additional arterial and venous samples (0.33 mL, respectively) were deposited in 0.5 mL
micro-centrifuge tubes containing 2M HCl and fixed inside 20 mL scintillation vials containing
1M NaOH to estimate hindlimb glucose oxidation rates as previously described (Posont et al.,
2021b). Vials were then sealed and incubated for 24 hours at room temperature. In vivo glucose
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oxidative metabolism is estimated by the amount of 14CO2 released from the blood by HCl and
recaptured by the NaOH at the bottom of the scintillation vial. Micro-centrifuge tubes were then
manually removed, and scintillation vials were filled with UltimaGold scintillation fluid (PerkinElmer). A liquid scintillation counter (Beckman-Counter 1900 TA, Brea, CA) was then used to
quantify radiolabeled 14CO2. Glucose oxidation by the hindlimb tissues was then calculated using
the difference in 14CO2 between arterial and venous samples at each given time of sample
collection. The response of the hindlimb tissues to insulin stimulation was determined by
calculating the fold-change in glucose oxidation between basal and HEC periods. Glucose uptake
was estimated by the difference in arterial and venous glucose concentrations. Technical
replicates at baseline and HEC levels were averaged.
Statistical Analysis
All data were analyzed with SAS 9.4 (SAS Institute, Cary, NC) using the mixed
procedure specific for repeated measures with the fetus as the experimental unit. Repeated
measures of blood parameters in the GSIS, HEC, and daily blood samples were analyzed for
effects due to treatment, time (dGA or period), and the interaction. Variables for time were
treated as repeated measures. Sex was treated as a random effect. Technical replicates were
averaged, and data are presented as mean ± standard error. Significant differences were declared
at α ≤ 0.05 and tendencies at α ≤ 0.10.

RESULTS
Daily Hematology
No group x dGA interactions were observed for any hematological measures. Total white
blood cell (WBC) concentrations tended to be greater (P = 0.09) in IUGR fetuses compared to
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controls and IUGR+EPA fetuses, regardless of dGA (Figure 2-1). Circulating lymphocytes were
greater (P < 0.05) in IUGR and IUGR+EPA and monocytes tended to be greater (P = 0.06) in
IUGR and IUGR+EPA fetuses compared to controls. Granulocytes, hematocrit (Hct), mean
corpuscular volume (MCV), hemoglobin concentrations (Hb), mean platelet volume (MPV), red
blood cells (RBC), and red blood cell width distribution (RWD) did not differ among
experimental groups. Hemoglobin concentrations were less (P < 0.05) in IUGR and IUGR+EPA
fetuses than controls (Figure 2-1). Platelet concentrations were greater (P < 0.05) in IUGR
fetuses compared to controls and were greater (P < 0.05) in IUGR+EPA fetuses than in IUGR
and control fetuses.
Daily Blood Gases and Metabolites
No group x dGA interactions were observed for blood glucose, lactate, pH, partial
pressure CO2 (pCO2), or partial pressure O2 (pO2). Daily blood glucose concentrations were less
(P < 0.05) in IUGR fetuses than controls regardless of day and was intermediate (P < 0.05) for
IUGR+EPA fetuses between controls and IUGR fetuses (Figure 2-3). Lactate concentrations
were greater (P < 0.05) in IUGR and IUGR+EPA fetuses compared to controls. Blood pH did
not differ among experimental groups. Blood pCO2 was greater (P < 0.05) and pO2 was less (P <
0.05) in IUGR and IUGR+EPA fetuses compared to controls. A group x dGA interaction (P <
0.05) was observed for daily blood HCO3 concentrations, which were greater (P < 0.05) in IUGR
and IUGR+EPA fetuses on dGA 122, 123, and 124. HCO3 was also greater (P < 0.05) in
IUGR+EPA than controls at dGA 120.
Glucose-Stimulated Insulin Secretion
Experimental group x glycemic period interactions were observed (P<0.05) for plasma
insulin and glucose-to-insulin ratios but not for blood glucose or lactate. Blood glucose was less
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(P<0.05) for IUGR fetuses than for controls and IUGR+EPA, regardless of period. Glucose was
also increased (P<0.05) during hyperglycemia compared to baseline for all groups (Figure 2-4).
Plasma insulin was less (P < 0.05) for IUGR fetuses than for controls and IUGR+EPA fetuses at
baseline. At hyperglycemia, plasma insulin was less (P < 0.05) in IUGR fetuses compared to
controls and was intermediate (P < 0.05) for IUGR+EPA between controls and IUGR fetuses.
Glucose-to-insulin ratios were less (P<0.05) for IUGR fetuses than for controls and IUGR+EPA
fetuses at baseline. At hyperglycemia, glucose-to-insulin ratios were less (P < 0.05) for IUGR
fetuses than controls and were intermediate (P < 0.05) for IUGR+EPA fetuses between controls
and IUGR fetuses. Blood lactate did not differ among treatment groups, regardless of period but
was greater (P<0.05) during hyperglycemia than baseline in all groups.
No group x period interactions were observed for blood pO2, pCO2, pH, hemoglobin,
hematocrit, hemoglobin bound O2 (O2HB), hemoglobin bound CO (COHB) or HCO3. Blood pO2
was less (P < 0.05) for IUGR fetuses than controls and was intermediate (P < 0.05) for
IUGR+EPA fetuses between IUGR fetuses and controls, regardless of period (Figure 2-5).
Blood pCO2 was greater (P < 0.05) for IUGR fetuses but not IUGR+EPA fetuses than for
controls and was greater (P < 0.05) during hyperglycemia than baseline regardless of
experimental group. Blood pH was less (P < 0.05) for IUGR fetuses and was intermediate (P <
0.05) for IUGR+EPA fetuses between IUGR fetuses and controls. It was also decreased (P <
0.05) during hyperglycemia compared to baseline regardless of experimental group. Blood
hemoglobin and hematocrit did not differ among experimental groups, regardless of period.
Blood O2HB was less (P < 0.05) in IUGR fetuses but did not differ between controls and
IUGR+EPA fetuses. It was also decreased (P < 0.05) during hyperglycemia in all experimental
groups. Blood COHB was less (P < 0.05) in IUGR fetuses compared to controls but did not
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differ from IUGR+EPA fetuses, regardless of period. Blood HCO3 was greater (P < 0.05) for
IUGR fetuses but less (P<0.05) for IUGR+EPA fetuses compared to controls, regardless of
period.
No group x period interactions were observed for Na +, K+, Cl-, or Ca2+ concentrations.
Blood Na+ was greater (P < 0.05) for IUGR fetuses but not IUGR+EPA fetuses than for controls,
regardless of period. Blood K+ was greater (P < 0.05) in IUGR fetuses and was intermediate (P <
0.05) for IUGR+EPA between controls and IUGR fetuses (Figure 2-6). Blood K+ decreased
during hyperglycemia, regardless of experimental group. Blood Cl- was greater (P < 0.05) for
IUGR fetuses than controls and IUGR+EPA fetuses, regardless of period. Blood Ca2+ did not
differ among experimental groups regardless of period.
No group x period interactions were observed for non-esterified fatty acids (NEFA),
blood plasma urea nitrogen (BUN), and high-density lipoprotein cholesterol (HDLc). Total
blood NEFA concentrations were greater (P < 0.05) in IUGR fetuses compared to controls and
IUGR+EPA fetuses (Figure 2-7). Blood NEFA were also decreased (P < 0.05) during
hyperglycemia compared to baseline in all groups. BUN were greater (P < 0.05) in IUGR fetuses
than controls, and were intermediate (P < 0.05) for IUGR+EPA fetuses between controls and
IUGR fetuses. HDLc did not differ between IUGR fetuses and controls but were greater (P <
0.05) in IUGR+EPA fetuses, regardless of period.
Hindlimb Glucose Metabolism
A group x insulinemic period interaction was observed (P < 0.05) for blood K+ but not for
any other blood parameters. Blood glucose was less (P < 0.05) in IUGR fetuses compared to
controls and was intermediate (P < 0.05) for IUGR+EPA fetuses between IUGR fetuses and
controls (Figure 2-8). Blood lactate tended to be greater (P < 0.10) in IUGR and IUGR+EPA
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than for controls. Blood pH was greater (P < 0.05) in IUGR fetuses than controls and
IUGR+EPA fetuses (Figure 2-9). Blood pCO2 did not differ among experimental groups but
blood pO2 was tended to be less (P < 0.10) in IUGR and IUGR+EPA compared to controls.
There was no difference among experimental groups for hemoglobin or hematocrit
concentrations (Figure-10). Blood plasma NEFA concentrations were greater (P < 0.05) in
IUGR fetuses and was intermediate (P < 0.05) for IUGR+EPA fetuses and controls. HCO3 was
less (P < 0.05) in IUGR fetuses than controls and IUGR+EPA fetuses.
Blood Na+ was greater (P < 0.05) in IUGR fetuses compared to controls and further
increased (P < 0.05) in IUGR+EPA fetuses compared to IUGR fetuses, regardless of insulinemic
period (Figure 2-11). A group x period interaction was observed (P < 0.05) for K+ which were
greater (P < 0.05) in IUGR fetuses than controls and intermediate for IUGR+EPA fetuses in the
baseline period. During HEC, blood K+ was greater (P < 0.05) in IUGR fetuses compared to
controls and less (P < 0.05) in IUGR+EPA fetuses compared to controls. Blood Cl- was greater
(P < 0.05) in IUGR fetuses than controls and greater (P < 0.05) in IUGR+EPA fetuses compared
to IUGR fetuses and controls, regardless of period. Blood Ca2+ was not different among
experimental groups but was increased (P < 0.05) during HEC.
Hindlimb glucose uptake rates were less (P < 0.05) for IUGR fetuses and IUGR+EPA
fetuses than controls (Figure-12). Similarly, hindlimb insulin-stimulated glucose oxidation was
less (P < 0.05) in IUGR and IUGR+EPA fetuses compared to controls.

DISCUSSION
In this study, we found that some but not all deficits caused by IUGR were mitigated by
daily infusion of fetuses with the anti-inflammatory ω-3 PUFA, EPA. The presence of systemic
inflammation was evident by elevated WBC in our IUGR fetuses. Total circulating populations

28
of WBC, lymphocyte, and monocytes were increased in the IUGR fetuses and total WBC
concentrations were recovered by 5-day EPA infusion to IUGR fetuses. Previous studies by our
lab (Barnes et al., 2019; Swanson et al., 2020) have demonstrated in adult animals that the
presence of increased leukocytes, granulocytes, lymphocytes, and monocytes are associated with
chronic heat stress even in the absence of direct immune challenges. The chronic heat stress used
in these studies produced many of the same physiological deficits as IUGR and demonstrates a
correlation between changes in immune profile and blood indicators of inflammation, such as
oxidative cellular stress and the secretion of inflammatory cytokines. In particular, the increase
in lymphocytes and monocytes in the IUGR fetuses of the present study support our hypothesis
that systemic inflammation occurs in IUGR fetuses. However, although the elevation of total
WBC was decreased by EPA infusions, lymphocytes and monocytes remained elevated in EPAinfused IUGR fetuses, suggesting that full mediation of the mechanisms stimulating immune cell
changes was not achieved. Surprisingly, platelet concentrations were increased only marginally
in saline-infused IUGR fetuses but were 122% greater than normal in EPA-infused IUGR
fetuses. We know from previous studies that increased circulating platelets are typically
associated with classical immune insults to the body (Koupenova et al., 2018), which was
perhaps an indirect component of this IUGR fetal model. Moreover, the further exacerbation by
ω-3 PUFA infusion was unexpected based on previous literature. In studies by Dyerberg and
Bang (1979) and Yamada et al. (1998), blood platelets were decreased in humans and rats
receiving ω-3 PUFA supplementation, respectively. It is unclear why our results differed, but we
would suspect there are other confounding mechanisms at work that may be responsible for these
alterations, such as transient hyperlipidemia from the hour-long ω-3 PUFA infusions.
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Daily blood glucose concentrations show that IUGR fetuses were moderately
hypoglycemic, which was an expected outcome of placental insufficiency. However, blood
glucose was partially recovered by daily EPA infusions. In contrast, blood lactate was increased
in IUGR fetuses and EPA-infused IUGR fetuses alike, suggesting that administration of EPA had
little effect on tissue glycolysis rates. Although we did not measure antioxidant status in our
fetuses, it is possible that increased oxidative stress and the associated stimulation of
inflammatory cytokine secretion (i.e., increase in inflammatory tone) impaired metabolic
function earlier and more profoundly than our late-term intervention could overcome (Renshaw
et al., 2010). Comparable impairments in blood pO2 and pCO2 between IUGR fetuses infused
with saline and those infused with EPA further support this possibility. Interestingly,
improvements in blood HCO3 due to EPA-infusion appeared to take time as HCO3 was increased
in IUGR fetuses and were not improved by EPA until the final day of the 5-day infusion period.
Circulating HCO3 plays a pivotal buffering role to protect against oxidative stress, and thus
increased HCO3 concentrations in our IUGR fetuses is likely a compensatory buffering response
that is ultimately made less necessary by daily ω-3 PUFA infusions.
Basal and glucose-stimulated insulin secretion, which were impaired by over 40% in our
IUGR fetuses, were each improved by 5-day ω-3 PUFA infusion. This indicates that deficits in
IUGR β cell function are at least in part due to enhanced inflammatory tone and thus benefit
from inflammatory mitigation. Despite complete recovery of basal insulin secretion, only partial
recovery of insulin secretion occurred under hyperglycemic conditions, indicating that there are
clearly factors other than inflammation also contribute to poor glucose-stimulus-secretion
coupling in the IUGR β cells. Although full islet morphology assessments were not performed,
our results may coincide with improved β cell mass, as previous studies showed that fetal β cell
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mass reduced by placental insufficiency directly leads to poor insulin secretion (Gatford and
Simmons, 2013). Moreover, fetal β cells require glucose for proper development, and EPA has
been shown to improve glucose uptake in other cell types (Figueras et al., 2011). Similar
improvements in β cells would help explain the better functionality observed here. In addition,
glucose-to-insulin ratios were recovered in IUGR fetuses receiving ω-3 PUFA treatment at
baseline and were partially recovered at hyperglycemia, and the hypoglycemia observed in
IUGR fetuses was also fully recovered. These results build upon our earlier studies that
demonstrated fetal inflammation in the IUGR fetus (Cadaret et al., 2019a; Posont and Yates,
2019) by showing that metabolic function in IUGR fetuses could be improved when fetal
inflammation is controlled.
Although previous studies suggested a shift to greater relative glycolytic lactate
production concomitant with a reduction in glucose the oxidation in the IUGR concentrations,
blood lactate concentrations did not differ among any of our groups under basal or
hyperglycemic conditions. However, this may have been due to a coincident increase in hepatic
lactate uptake, which would be consistent with increased Cori Cycle activity in the IUGR fetus
(Thorne et al., 2014). Nevertheless, increased lactate production can cause insulin resistance in
IUGR individuals (Kim et al., 2019), and previous work by us and others shows that limited
capacity for glucose oxidation in favor of lactate production provides carbon substrates for
hepatic glucose production in the IUGR fetus (Brown et al., 2015; Cadaret et al., 2019a). As
expected, blood pH was decreased in our IUGR fetuses, despite our observation of greater blood
HCO3. Unlike HCO3, however, blood pH was partially recovered by EPA infusion. Controlling
fetal inflammation with ω-3 PUFA also improved CO2 and O2, which were predictably increased
and decreased by IUGR, respectively. Although a beneficial outcome, it is unclear from this
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study whether these improvements were due to change in placental function or fetal metabolism,
and thus follow-up studies are warranted. Together, these findings further support our hypothesis
that skeletal muscle glucose metabolism in IUGR fetuses reflects a key nutrient-sparing
mechanism.
In addition to the adaptive change in glucose metabolism, lipid homeostasis and protein
cycling may also be altered in the IUGR fetus. NEFA concentrations are indicative of increased
lipolytic activity and are consistent with increased fat mobilization and/or decreased fat
deposition, which is a hallmark of IUGR (Ortega-Senovilla et al., 2010; Yates et al., 2018). In
our present study, IUGR fetuses exhibited increased blood NEFA concentrations that were
completely resolved in EPA-infused IUGR fetuses, demonstrating a beneficial effect of these
long-chain fatty acids in lipid homeostasis. Moreover, BUN levels were increased in IUGR
fetuses but were lower in EPA-infused IUGR fetuses than IUGR fetuses and controls. We
postulate that this was indicative of less protein catabolism, although we cannot rule out the
possibility of increased kidney function. Indeed, decreased renal blood flow has been observed
previously in IUGR fetuses and suggested disturbance of renal function (Todros et al., 1999).
Thus, increased BUN in the blood of IUGR fetuses could have been due at least in part to a lack
of filtration of residual urea, causing it to accumulate in the bloodstream. Interestingly, HDLc
was not affected by IUGR alone, but was increased by EPA infusions. Considering the function
of HDLc molecules, we presume that there were being taken from peripheral tissue back to the
liver at greater rates. This occurs for the attached cholesterol to be utilized as precursor for bile
salts, after which and is the HDL is esterified and returned to the liver (Gupta and Rajagopal,
2007). Because of this, it would be reasonable to expect the increase in circulating PUFA due to
EPA infusion would make additional bile salts to break down EPA.

32
Hyperinsulinemic Euglycemic Clamp
Similar to our results during daily and hyperglycemic clamp assessments, blood glucose
was diminished by approximately 64% in IUGR fetuses during the basal and hyperinsulinemic
periods of the HEC study. However, these concentrations were partially rescued by infusion of
EPA. Conversely, blood lactate concentrations were increased in IUGR fetuses and were not
improved by EPA infusions. Together with other stress factors, the impact of lactate levels on
insulin resistance in IUGR tissues could be a contributor to and/or cause of the change in glucose
metabolism (Kim et al., 2019). Regardless, lactate production provides substrates for hepatic
glucose production in the IUGR fetus via the Cori Cycle, since glucose itself cannot leave
skeletal muscle (Brown et al., 2015; Cadaret et al., 2019a).These results allow us to postulate
that, although glycemia was partially recovered, the lack of differences for blood lactate
concentrations may be explained by increased hepatic lactate utilization that offsets the presumed
increase in secretion of lactate by muscle. This, more direct studies of lactate production rates are
needed. In contrast to lactate, blood pH was increased in IUGR fetuses, but was recovered by
daily EPA infusion. This would indicate that more mechanisms than just lactate were influencing
blood pH. For example, although pCO2, which was recovered in the daily blood samples as well
as during the hyperglycemic clamp did not differ among groups during the HEC study, which
might help explain the paradoxical rise in pH which had previously been less in out IUGR
fetuses.
Poor skeletal muscle glucose uptake is a well-characterized hallmark of IUGR fetuses
and offspring (Cadaret et al., 2019c; Yates et al., 2019; Posont et al., 2021b). Thus, it was not
surprising that in the present study, hindlimb glucose uptake was reduced by 400% in the IUGR
fetuses in the present study. It was somewhat unexpected, however, that EPA-infusion resulted in
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no improvement. This suggests that EPA was not successful in recovering glucose uptake despite
our other evidence that inflammation was the underlying mechanism for this deficit. This
contrasted previous findings in the literature, specifically when evaluating the effect of the ω-3
PUFA, EPA, on GLUT4 translocation, which is the rate-limiting step for insulin-stimulated
glucose uptake (Kim et al., 2019). However, preserved glucose uptake in IUGR fetuses has been
observed previously (Limesand et al., 2007; Brown et al., 2015) and it is worth noting that only
about 40% of the hindlimb tissues are skeletal muscle (Hicks and Yates, 2021). Nevertheless, the
response of skeletal muscle glucose oxidation rates to insulin was markedly impaired in the
IUGR fetuses, and this deficit was not improved by EPA-infusion. Indeed, the 8-fold change in
glucose oxidation observed when uncompromised fetuses were infused with insulin only
increased 3-fold in IUGR fetuses, whether infused with saline or EPA. This suggests that
although several components of glucose homeostasis were improved by daily EPA infusion into
IUGR fetuses, insulin-mediated metabolic processes in the hindlimb tissues were not.
Together, these findings allow us to conclude that multiple factors contributing to the
dynamic dysregulation of glucose homeostasis in the late-term IUGR fetus were improved by
controlling fetal systemic inflammation through EPA infusion. Improvements in insulin secretion
indicated that pancreatic β cell function was recovered. However, other important indicators of
metabolic function and health remained deficient. This provides direction to the next step in
order to determine what additional programming mechanisms must be targeted for a broader
improvement in metabolism. Nevertheless, results of the current study indicate that moderation
of fetal inflammation via EPA supplementation can have a beneficial impact on developmental
programming of IUGR.
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Figure 2-1. Daily total white blood cell (A), lymphocyte (B), monocyte (C), and granulocyte (D)
concentrations from Control (n=12), IUGR (n=5), and IUGR+EPA (n=6) fetuses. a,b means with
differing superscripts differ (P<0.05). x,y means with different superscripts tend to differ (P < 0.10).
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Figure 2-2. Data are shown for daily hematocrit percentage (A), hemoglobin (B), mean corpuscular
volume (C), red blood cell width distribution (D), red blood cells (E) and platelet count (D) from Control
(n=12), IUGR (n=5), and IUGR+EPA (n=6) fetuses. a,b means with differing superscripts differ
(P<0.05).

36

Figure 2-3. Daily blood glucose (A), pH (B), partial pressure O2 (C), blood lactate (D), HCO3 (E) and
partial pressure CO2 (D) from Control (n=12), IUGR (n=5), and IUGR+EPA (n=6) fetuses. a,b means
with differing superscripts differ (P<0.05).
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Figure 2-4. Blood glucose (A), glucose-to-insulin ratio (B), plasma insulin (C), and blood lactate (D)
concentrations determined at basal and hyperglycemic conditions. Data are shown for Control (n=12),
IUGR (n=3), and IUGR+EPA (n=4) fetuses. a,b means with differing superscripts differ (P<0.05).
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Figure 2-5. Data are shown for pH (A), partial pressure O2 (B), partial pressure CO2 (C), HCO3 (D),
hemoglobin (E), and hematocrit % (D) at basal and hyperglycemic conditions. Data are shown for Control
(n=12), IUGR (n=3), and IUGR+EPA (n=4) fetuses.
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Figure 2-6. Na+ (A), K+ (B), Cl- (C), and Ca2+ (D) measures are reported at basal and hyperglycemic
conditions. Data are shown for Control (n=12), IUGR (n=3), and IUGR+EPA (n=4) fetuses.
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Figure 2-7. Data are shown for plasma blood urea nitrogen (A), plasma HDLC (B), and plasma NEFA
concentrations (C) for Control (n=12), IUGR (n=3), and IUGR+EPA (n=4) fetuses. a,b means with
differing superscripts differ (P<0.05).
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Figure 2-8. Blood glucose at arterial (A), venous (B), arteriovenous difference (C). Blood lactate at
arterial (D), venous (E), and the arteriovenous difference (F). Data are shown at basal and HEC
conditions for Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses.
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Figure 2-9. Blood pH (A), HCO3 (B), partial pressure O2 (C), and partial pressure CO2 (D) at basal and
HEC conditions. Data are shown for Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses.
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Figure 2-10. Data are shown for hemoglobin (A), hematocrit % (B), and plasma NEFA (C) are shown at
basal and HEC for Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses. a,b means with differing
superscripts differ (P<0.05).
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Figure 2-11. Basal and HEC concentrations for Na+ (A), K+ (B), Cl- (C), and Ca2+ (D) are shown for
Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses.
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Figure 2-12. Insulin sensitivity for hindlimb skeletal muscle glucose oxidation during steady-state
hyperinsulinemia measured by fold change from basal and hyper insulinemic-euglycemic conditions.
Data are shown for Control (n=3), IUGR (n=4), and IUGR+EPA (n=6) fetuses. a,b means with differing
superscripts differ (P<0.05).
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Chapter 3

Fetal growth, body composition, and ex vivo glucose metabolism are impaired in the IUGR
fetal sheep but are improved by daily ω-3 PUFA infusion.

ABSTRACT
Chronic maternal stress during peak placental development yields placental
insufficiency-induced intrauterine growth restriction (IUGR) and causes biometric and
metabolic deficits in the late-term fetus and offspring. Placental insufficiency limits nutrient
transfer across the placenta, which forces the fetus to adapt its physiological processes for
growth and metabolism in order to survive. These adaptations repartition limited nutrients to
vital tissues and organs, and thus less vital tissues such as skeletal muscle are compromised by
decreased growth potential and impaired metabolic capacity. In this study, IUGR fetal sheep
were produced using the maternal hyperthermia model while controls were housed at
thermoneutral conditions. Indwelling fetal femoral catheters were placed at 118 days of gestation
(dGA) to allow for daily intravenous (i.v.) infusion of IUGR fetuses with eicosapentaenoic acid
(EPA) (IUGR+EPA; n=6) or EtOH-spiked (EtOH) saline placebo (IUGR; n=5) and controls
with an EtOH-saline placebo (n=12). Infusions were administered for 5 ±1 d beginning at 120 ±1
dGA. Necropsy was performed at 126 ±1 dGA and fetal biometrics were assessed. IUGR fetuses
were lighter (P < 0.05) than controls but IUGR+EPA bodyweight was partially recovered. IUGR
fetuses also exhibited reduced (P < 0.05) hindlimb, semitendinosus (ST), and longissimus dorsi
(LD) masses and tended to exhibit reduced (P < 0.10) soleus mass compared to controls. EPA
infusion increased (P < 0.05) hindlimb, ST, and LD mass and tended to increase (P < 0.10)
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soleus and ST mass compared to saline-infused IUGR fetuses. Flexor digitorum superficialis
(FDS) muscle mass did not differ among groups. IUGR reduced (P < 0.05) heart, lung, and
kidney mass and tended to reduce (P < 0.10) liver mass. EPA infusion recovered (P < 0.05) lung
and kidney mass and tended to recover (P < 0.10) liver mass but did not improve heart mass.
Brain mass did not differ among groups. Fiber type proportions in the ST were estimated by
myosin heavy chain ratios determined by electrophoresis. Myosin for Type I fibers did not differ
among groups, but myosin for Type IIA fibers tended to be decreased (P < 0.10) and myosin for
Type IIx fibers tended to be increased (P < 0.10) in IUGR fetuses compared to controls. EPA
infusion tended (P < 0.10) to recover myosin ratios for two of these fiber types. ST glycogen
content was not different among groups. Ex vivo analysis of skeletal muscle specific glucose
metabolism indicated a decrease (P < 0.05) in glucose uptake for IUGR fetal muscle that was
partially recovered (P < 0.05) by EPA infusion. Likewise, glucose oxidation rates were impaired
(P < 0.05) for IUGR fetal muscle but were fully recovered by EPA infusions. From these
findings, we can conclude that daily administration of ω-3 PUFA directly to the fetus was
effective in improving several biometric and metabolic deficits in late-term IUGR fetuses.
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INTRODUCTION
Acute stress is beneficial for a multitude of reasons, including its activation of growth
factor synthesis and physiological alterations as part of the fight or flight response (Weissman,
1990). However, prolonged stress exposure in pregnant animals is detrimental to the life-long
health of offspring (Hales and Barker, 1992). Placental insufficiency-induced intrauterine growth
restriction (IUGR) occurs as a result of chronic maternal stress during peak placental
development, which causes stunting of the placenta by re-routing uterine blood flow (Murphy et
al., 2006; Brown et al., 2015). Placental stunting results in a limited supply of nutrients to the
fetus and therefore prompts fetal stress responses that induce nutrient-sparing adaptive
mechanisms (Limesand et al., 2007; Brown et al., 2015; Dunlop et al., 2015). Although these
adaptations ensure intrauterine survival, they lead to programmed deficits such as impaired
myogenesis, asymmetric growth, and dysregulation of glucose metabolism that persist after birth
(Yates et al., 2014; Cadaret et al., 2019c; Gibbs et al., 2020). Such adaptive mechanisms appear
to occur in part as a response to systemic inflammation and remain even when the systemic
inflammation is alleviated after birth. Therefore, the objective of this study was to evaluate the
effectiveness of daily ω-3 polyunsaturated fatty acids (PUFA) infusions on fetal IUGR sheep in
order to mediate inflammation. Previous literature has established the effectiveness of ω-3 PUFA
in decreasing inflammatory signaling (Caughey et al., 1996; Velten et al., 2014; Allam-Ndoul et
al., 2016; Kim et al., 2019). Thus, use of this nutraceutical in mediating the fetal inflammatory
response may improve metabolism and biometric deficits. We hypothesized that these deficits
will be improved by daily infusion of IUGR fetuses with the ω-3 PUFA, eicosapentaenoic acid
(EPA), in late gestation.
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MATERIALS & METHODS
Animals and Experimental Design
These studies were approved by the Institutional Animal Care and Use Committee at the
University of Nebraska-Lincoln, an AAALAC International-accredited institution. The wellcharacterized maternal hyperthermia model was used to generate placental insufficiency induced
IUGR fetal sheep as previously described by Yates et al. (2016) and Cadaret et al. (2018).
Briefly, gestating ewes were exposed to elevated ambient conditions of 40°C and 35% relative
humidity during peak placental development (dGA 40-95) before returning to thermoneutral
conditions (25°C) alongside their control counterparts. This study utilized time-mated Polypay
ewes to carry control and IUGR fetuses. Indwelling catheters were placed at 118 dGA in the
femoral vein and artery of the fetus as previously described (Cadaret et al., 2019a).
Catheterizations allowed for the daily infusion of fetuses. IUGR fetuses were randomly assigned
to receive daily infusions of 0.25 mg/d EPA (i.e., IUGR+EPA; n=6) or saline placebo (i.e.,
IUGR; n=5) from dGA 121 to 125 ± 1 d. Control fetuses (n=12) also received a saline infusion.
Infusions were administered intravenously (i.v.) into the fetal femoral vein over a period of 1
hour. Animals were euthanized at dGA 125 ± 1 d by double barbiturate overdose and tissue and
organ metrics were assessed. Fetal bodyweight and total hindlimb mass were recorded in
addition to masses for semitendinosus (ST), soleus, longissimus dorsi (LD), and flexor digitorum
superficialis (FDS) muscles. Organ metrics included heart, lung, liver, kidney, and brain masses.
Ex Vivo Glucose Metabolism
Flexor digitorum superficialis (FDS) and soleus muscles were collected at necropsy for
ex vivo analysis of glucose metabolism. Muscle was washed in ice-cold Phosphate-buffered
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saline solution (PBS), and strips were split from tendon-to-tendon, creating at 50 ± 5 mg strips.
Strips were pre-incubated for 1 hour in Krebs-Heneslit Buffer (KHB) spiked with no additive
(basal), or insulin (5 mU/ml Humulin-R). Muscle strips were then washed in respectively-spiked
glucose-free KHB media for 20 min. Glucose oxidation was measured using sealed dual-well
chambers as previously described (Cadaret et al., 2017). Briefly, muscle strips were incubated in
KHB spiked with 5 mM [14C-U] D-glucose for 2 hr. The adjacent well contained 1M NaOH.
Chambers were then cooled on ice and wells containing muscle strips were injected with 2M
HCl and allowed to incubate at 4°C for an additional 1 hr. During this final incubation,
bicarbonate-bound 14CO2 was liberated from the media and captured by the NaOH. The
forementioned NaOH was collected and deposited in a 20-mL scintillation vial and filled with
with UltimaGold scintillation fluid (Perkin-Elmer). Vials were assessed with an LC counter
(Beckman-Counter 1900 TA, Brea, CA) to measure 14CO2 concentrations. To measure glucose
uptake, muscle strips were incubated in KHB media containing no additive (basal) or insulin (5
mU/ml Humulin-R) and 1 mM [3H] 2-deoxy-d-glucose for 20 min. Following incubation, muscle
strips were cooled and washed in PBS, and placed in 20-mL scintillation vials with 2M NaOH to
be lysed at 37°C for 2 hours. Liquid scintillation was then used to determine the concentration of
[3H] 2-deoxy-d-glucose for each lysate.
Myosin Heavy Chain Electrophoresis
At necropsy, 100 mg of snap-frozen ST muscle was collected, homogenized, and sonified
in 400 μl of RIPA buffer (Thermo Fisher). Samples were then centrifuged (14,000 x g, 2min,
4°C) and supernatant was collected. Pierce BCA Assay (Thermo Fisher) was used to measure
total protein content. Samples were then combined with Bio-Rad 4× Laemmli Sample Buffer
(Bio-Rad, Hercules, CA) and dry-boiled for 10 minutes at 70°C. Samples were then equilibrated
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to room temperature and 40 μg of protein was loaded into each well. Upper running buffer
contained 100 mM Tris, 150 mM glycine, 0.1% SDS, and 0.07% 2β-mercaptoethanol in distilled
water, and the lower running buffer consisted of 50 mM Tris, 75 mM glycine, and 0.05% SDS in
distilled water. Mini-PROTEAN gradient gels (4-15%; Bio-RAD). Electrophoresis was
performed at room temperature on a PowerPac Basic (Bio-RAD) at a constant voltage of 110V
for 3 hours. Following electrophoresis, gels were stained overnight in Gel-Code Blue (Thermo
Fischer) at room temperature, washed in distilled water, and imaged using an Odyssey infrared
imaging system (LI-COR Biosciences, Lincoln, NE). Quantification of MyHC-I, MyHC-IIA,
and MyHC-IIx was completed by densitometry (Image Studio Lite Ver 5.0; LI-COR) in order to
estimate fiber type ratios.
Glycogen Colorimetric Assay
Snap-frozen ST muscle samples (100 mg) were homogenized with 1 mL distilled water
and sonicated. Homogenates were boiled (95°C x 5 minutes), centrifuged (13,000g x 5 minutes),
and supernatant was collected. Samples were diluted in Hydrolysis buffer (Sigma-Aldrich) at
1:200. Glycogen content was then measured by a commercial Glycogen Assay Kit (SigmaAldrich, St. Louis, MO). Inter- and intra- assay coefficients of variance were less than 15%.
Statistical Analysis
All data were analyzed with SAS 9.4 (SAS Institute, Cary, NC) using the mixed
procedure, with the fetus as the experimental unit. Sex was treated as a random effect. Technical
replicates were averaged, and data are presented as mean ± standard error. Significant
differences were declared at α ≤ 0.05 and tendencies at α ≤ 0.10.
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RESULTS
Fetal Biometrics
At necropsy, fetal body weight was 23% less (P < 0.05) for IUGR fetuses than for
controls and was intermediate (P < 0.05) for IUGR+EPA fetuses (Table 3-1). Fetal hindlimbs
were lighter (P < 0.05) for IUGR fetuses but not for IUGR+EPA fetuses than for controls. ST
muscle mass was less (P < 0.05), and soleus muscle mass tended to be less (P < 0.10) for IUGR
fetuses than controls and were intermediate (P < 0.05) for IUGR+EPA fetuses. LD muscle mass
was less (P < 0.05) for IUGR fetuses but not for IUGR+EPA fetuses than for controls. FDS
muscle mass did not differ among groups. Heart mass was less (P < 0.05) and liver mass tended
to be less (P < 0.05) for IUGR and IUGR+EPA fetuses than for controls. Lung mass and kidney
mass were lighter (P < 0.05) for IUGR fetuses but not for IUGR+EPA fetuses than for controls.
Brain mass did not differ among experimental groups.
Ex vivo Skeletal Muscle Glucose Metabolism
Glucose uptake rates in FDS and soleus muscle were 36% less (P < 0.05) for IUGR fetal
muscle than controls but were only 14% less (P < 0.05) for IUGR+EPA fetal muscle, regardless
of media conditions (Figure 3-1). Glucose oxidation likewise was less (P < 0.05) for IUGR fetal
muscle compared to controls, but fully recovered in IUGR+EPA fetal muscle compared to
controls, regardless of media conditions. Glucose oxidation was increased (P < 0.05) when
muscle was incubated in insulin-spiked media compared to basal media, regardless of
experimental group.
Skeletal Muscle Composition
Proportions of MyHC-I in ST protein isolates did not differ among groups. However,
both MyHC-IIA and MyHC-IIx proportions tended to be less (P < 0.10) in the IUGR fetus

53
compared to IUGR+EPA fetuses and controls (Figure 3-2).. Semitendinosus glycogen content
did not differ among groups.

DISCUSSION
In this study, we found that biometric deficits in the IUGR fetus were consistent with the
decreased muscle mass and asymmetric growth as previously observed (Cadaret et al., 2019c;
Yates et al., 2019; Posont et al., 2021b). However, targeting systemic inflammation in these
fetuses provided promising results that indicate improvement in total body and muscle-specific
growth. As expected, bodyweight was less in IUGR fetuses because of restricted growth in utero.
Moreover, partial recovery of several growth and body symmetry metrics indicates that EPA
administration is effective on potential intervention for biometric deficits. In fact, the mass of the
hindlimb, two of the three hindlimb muscles (ST and soleus) and the LD, were fully recovered
by this daily ω-3 PUFA regimen of EPA. The importance of skeletal muscle to metabolic health
and glucose homeostasis cannot be overstated, as it clears 65% of total glucose from circulation
(Yates et al., 2018). Thus, improved muscle mass almost assuredly contributed to improved
glucose-to-insulin ratios reported in the previous chapter. Improved muscle mass presumably
increased the capacity for glucose utilization and oxidation independent of any changes in
metabolic function proper. Consistent with known nutrient repartitioning mechanisms, our IUGR
fetuses developed smaller hearts, lungs, livers, and kidneys (Brown et al., 2015; Dunlop et al.,
2015). Daily ω-3 PUFA administration of EPA was successful in recovering lung and kidney
size but did not improve heart or liver mass. The later observations were somewhat unexpected,
as both heart and liver appeared to be priority tissues for preserved growth in earlier studies
(Cadaret et al., 2019a; Posont et al., 2021a). Nevertheless, comparable brain weights among the
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three groups indicates that growth of the fetus’ highest priority, neural tissue, was indeed
maintained.
Deficits in skeletal muscle-specific glucose metabolism observed in IUGR fetuses was
improved by ω-3 PUFA in our ex vivo analysis. Inflammation in the IUGR fetuses presumably
decreased translocation of GLUT-4 transporters which is the rate-limiting mechanism for
insulin-stimulated glucose uptake (Lorenzo et al., 2008). Although this study did not directly
assess GLUT-4, the results of decreased glucose uptake was observed in muscle from IUGR
fetuses. Kim et al. (2019) provided a description of the mechanism by which EPA increases
AMP:ATP ratios, thus increasing phosphorylation of AMP-activated protein kinase (AMPK).
This AMPK activation step is important in the general regulation of cellular growth and
metabolism but acts in part by increasing translocation of GLUT-4 in muscle. Whether by this or
other mechanisms, our study found a partial recovery of glucose uptake when IUGR fetuses were
infused with EPA, suggesting that inflammatory mediation was at least partially inhibiting
inflammatory action and, in turn, reducing glucose uptake. In addition to glucose uptake, we
observed reduced glucose oxidation rates in muscle from IUGR fetuses. This was expected based
on the findings of previous studies that reported reduced whole-body glucose oxidation in IUGR
fetal sheep (Limesand et al., 2007; Brown et al., 2015). Brown et al. (2015) described this as
being the result of a shift in metabolism to greater lactate production concurrent with a reduced
conversion of pyruvate to acetyl coA. Ultimately, this resulted in downstream changes that
decreased the capacity for glucose oxidation, regardless of insulin stimulation. In our study,
glucose oxidation was reduced by 28% in the IUGR fetal muscles but was recovered in both
basal and insulin-spiked media when the muscle strips were from IUGR fetuses that had received
ω-3 PUFA infusions.
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Decreased Type I and IIA muscle fibers in IUGR fetuses are correlated with insulin
insensitivity and altered glycolytic enzyme activity (Jensen et al., 2007). As such a shift in
relative numbers from Type I and IIA fibers, which are oxidative in nature, to Type IIx fibers,
which are glycolytic, would have obvious detrimental effects on glucose oxidation (Yates et al.,
2016). Although myosin heavy chain indicators assessed in this study indicated that Type I fibers
were not decreased in numbers by IUGR, decreased number of Type IIA fibers and increased
numbers of Type IIx fibers was consistent with reduced glucose oxidation found in this study.
Moreover, although ω-3 PUFA infusion unexpectedly failed to improve glucose oxidation in
vivo, the combined findings of improved Type IIA fiber ratios and improved ex vivo glucose
oxidation, indicate that ω-3 PUFA infusion was indeed beneficial for muscle glucose
metabolism. Furthermore, the recovery of glucose oxidation ex vivo was independent of insulin
activity. This likely explains the lack of an effect in vivo, as hindlimb glucose oxidation was
assessed as the responsiveness to insulin stimulation.

IMPLICATIONS
The growth and metabolic deficits imposed by IUGR have been widely established in literature.
These deficits, which result from physiological adaptations made in utero, yield prenatal and
postnatal consequences for offspring. Nutraceutical moderation of inflammatory signaling in
these fetuses, however, appeared to pose a promising intervention strategy to improve the
pathological outcomes of these programming deficits. This study demonstrates that ω-3 PUFA
was dynamically effective at recovering biometric deficits and partially recovering skeletal
muscle-specific glucose metabolism. Although a fundamental step in establishing their efficacy,
i.v. infusions of ω-3 PUFA are not feasible for humans or livestock producers, and therefore
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further research is warranted to evaluate the effectiveness of administering EPA maternally via
the diet or otherwise to target the fetus through placental transfer.
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Figure 3-1. Proportion of myosin heavy chains, Type 1, 2A, and 2X, are shown for Control (n=12),
IUGR (n=4), and IUGR+EPA (n=4) fetuses. x,y means with differing superscripts tend to differ (P<0.10).

58

Figure 3-2. Ex vivo hindlimb specific glucose metabolism was assessed at necropsy by isolation of FDS
and soleus muscle. Glucose uptake (A) and oxidation (B) are reported for Control (n=12), IUGR (n=5),
and IUGR+EPA (n=6) fetuses.
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Table 3-1. Fetal biometrics for ω-3 PUFA-infused IUGR fetal sheep.

Mass
Control

IUGR

IUGR+EPA

Fetal Weight, kg

3.1 ± 0.1a

2.4 ± 0.2b

2.9 ± 0.1c

0.03

Hindlimb, g

308 ± 13a

238 ± 20 b

294 ± 17 a

0.04

ST, g

6.5 ± 0.3a

4.5 ± 0.5b

5.5 ± 0.4c

0.03

Soleus, g

1.03 ± 0.13x

0.63 ± 0.11y

0.89 ± 0.15z

0.09

LD, g

61 ± 3a

47 ± 2b

60 ± 2a

< 0.001

FDS, g

5.57 ± 0.39

3.83 ± 0.88

5.66 ± 0.45

NS

Heart, g

27.1 ± 1.3a

21.5 ± 1.4b

24.1 ± 1.4b

0.02

Lungs, g

101 ± 4a

88 ± 3b

95 ± 4a

0.02

Liver, g

121 ± 8 x

102 ± 8y

104 ± 7y

0.07

Kidneys, g

21.8 ± 1a

13.9 ± 1.7b

20.5 ± 1.3a

<0.001

Brain, g

45.1 ± 1.3

41.5 ± 2.1

41.7 ± 1.6

NS

Data are presented as mean ± SE.
a,b,c

x,y,z

P-Value

Experimental Group

means with different superscripts differ (P < 0.05).
means with different superscripts tend to differ (P < 0.10).

NS, not significant.
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